Safety of insulin lispro: Pooled data from clinical trials

American Journal of Health-System Pharmacy

Volumn 56, Issue 6, 1999, Pages 542-547

  Glazer, N Bradly ^a   Zalani, Sunita ^a   Anderson Jr , James H ^a   Bastyr III, Edward J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathies; Drug comparisons; Insulin human; Insulin lispro; Insulins; Toxicity

Indexed keywords

INSULIN LISPRO; ISOPHANE INSULIN;

ABDOMINAL PAIN; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG SAFETY; EYE TOXICITY; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSULIN TREATMENT; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; THORAX PAIN; UROGENITAL TRACT DISEASE; NEUROLOGIC DISEASE; OTOTOXICITY;

EID: 0343527215     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.6.542     Document Type: Article

References (23)

1. Howey DC, Bowsher RR, Brunelle RL et al. [Lys(B28)Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994; 43:396-402.
2. Torlone E, Fanelli C, Rambotti AM et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM. Diabetologia. 1994; 37:713-20.
3. Anderson JH, Brunelle RL, Koivisto VA et al. Improved meal-time treatment of diabetes mellitus using an insulin analogue. Clin Ther. 1997; 19:62-72.
4. Ebeling P, Jansson P, Smith U et al. Strategies toward improved control during insulin lispro therapy in IDDM: importance of basal insulin. Diabetes Care. 1997; 20:1287-9.
5. Anderson JH, Brunelle RL, Koivisto VA et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997; 46:265-70.
6. Holleman F, Schmitt H, Rottiers R et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care. 1997; 20:1827-32.
7. Anderson JH, Brunelle RL, Keohane P et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin dependent diabetes mellitus. Arch Intern Med. 1997; 157:1249-55.
8. Pfutzner A, Kustner E, Forst T et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes. 1996; 104(1):25-30.
9. Bastyr EJ III, Kotsanos J, Vignati L et al. Insulin lispro (LP) reduces hypoglycemia rate in persons with type II diabetes at high risk for hypoglycemia. Diabetes. 1996; 45(suppl 2):56A. Abstract.
10. Vignati L, Anderson JH Jr, Iversen PH. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin dependent diabetes mellitus. Clin Ther. 1997; 19:1408-21.
11. Rowe R, Anderson JH, Gale E. A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen. Diabetes. 1996; 45(suppl 2):71A. Abstract.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
13. Henricsson M, Nilsson A, Janzon L et al. The effect of glycemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med. 1997; 14:123-33.
14. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103-17.
15. Holcombe JH, Zalani S, Arora V. Comparative study of insulin lispro and regular insulin in 481 adolescents with type 1 diabetes. Diabetologia. 1997; 40(1):A344. Abstract.
16. Holcombe JH, Zalani S, Arora V et al. Insulin lispro (LP) results in less nocturnal hypoglycemia compared with regular human insulin in adolescents with type 1 diabetes. Diabetes. 1997; 46(1):103A. Abstract.
17. Garg SK, Carmain JA, Braddy KC et al. Pre-meal insulin analogue insulin lispro vs humulin (r) insulin treatment in young subjects with type 1 diabetes. Diabet Med. 1996; 13:47-52.
18. Kitzmiller JL, Buchanan TA, Kjos S et al. Preconception care of diabetes, congenital malformations, and spontaneous abortions. Diabetes Care. 1996; 19:514-41.
19. Becerra JE, Khoury MJ, Cordero JF et al. Diabetes mellitus during pregnancy and risks for specific birth defects: a population-based control study. Pediatrics. 1990; 85:1-9.
20. Buelke-Sam J, Byrd RA, Hoyt JA et al. A reproductive and developmental toxicity study in CD rats of LY275585, [Lys(B28),Pro(B29)]-insulin toxicity. J Am Coll Toxicol. 1994; 13:247-60.
21. Veciana M, Major C, Morgan M et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995; 333:1237-43.
22. Jovanovic L, Ilic SS, Gutieritz M et al. Insulin lispro (LP) improves postprandial glucose (PPG) without increased immunogenicity or hypoglycemia in gestational diabetic women (GDW). Diabetes. 1998; 17(1):A49. Abstract.
23. Humalog package insert. Indianapolis, IN: Eli Lilly and Company; 1996 Sep.